LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: CTLA4-Ig in combination with FTY720 promotes allograft survival in sensitized recipients.

Khiew, Stella H / Yang, Jinghui / Young, James S / Chen, Jianjun / Wang, Qiang / Yin, Dengping / Vu, Vinh / Miller, Michelle L / Sciammas, Roger / Alegre, Maria-Luisa / Chong, Anita S

JCI insight

2017  Volume 2, Issue 9

Abstract: ... cell expansion and trafficking into the allograft with CTLA4-Ig and FTY720 can promote allograft ... survival in allosensitized recipients. ... rejection was observed in 50% of recipients by day 35 after transplantation. When CTLA4-Ig was combined ...

Abstract Despite recent evidence of improved graft outcomes and safety, the high incidence of early acute cellular rejection with belatacept, a high-affinity CTLA4-Ig, has limited its use in clinical transplantation. Here we define how the incomplete control of endogenous donor-reactive memory T cells results in belatacept-resistant rejection in an experimental model of BALB/c.2W-OVA donor heart transplantation into C57BL/6 recipients presensitized to donor splenocytes. These sensitized mice harbored modestly elevated numbers of endogenous donor-specific memory T cells and alloantibodies compared with naive recipients. Continuous CTLA4-Ig treatment was unexpectedly efficacious at inhibiting endogenous graft-reactive T cell expansion but was unable to inhibit late CD4+ and CD8+ T cell infiltration into the allografts, and rejection was observed in 50% of recipients by day 35 after transplantation. When CTLA4-Ig was combined with the sphingosine 1-phosphate receptor-1 (S1PR1) functional antagonist FTY720, alloantibody production was inhibited and donor-specific IFN-γ-producing T cells were reduced to levels approaching nonsensitized tolerant recipients. Late T cell recruitment into the graft was also restrained, and graft survival improved with this combination therapy. These observations suggest that a rational strategy consisting of inhibiting memory T cell expansion and trafficking into the allograft with CTLA4-Ig and FTY720 can promote allograft survival in allosensitized recipients.
Language English
Publishing date 2017-05-04
Publishing country United States
Document type Journal Article
ISSN 2379-3708
ISSN (online) 2379-3708
DOI 10.1172/jci.insight.92033
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top